Trial Profile
A Multi-Site, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7239361 (BMS-986089) in Ambulatory Boys With Duchenne Muscular Dystrophy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Jan 2024
Price :
$35
*
At a glance
- Drugs Talditercept alfa (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms Thunderjet
- Sponsors Bristol-Myers Squibb; Roche
- 08 Jan 2024 Results from NCT02515669 and NCT03039686 , published in the Neurology and Therapy
- 26 May 2020 Status changed from completed to discontinued.
- 11 May 2020 Status changed from active, no longer recruiting to completed.